Drugging the undruggable RAS: Mission Possible?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Drugging the undruggable RAS: Mission Possible?

Published:2014-10-17 Issue:11 Volume:13 Page:828-851
ISSN:1474-1776
Container-title:Nature Reviews Drug Discovery
language:en
Short-container-title:Nat Rev Drug Discov

Author:

Cox Adrienne D.,Fesik Stephen W.,Kimmelman Alec C.,Luo Ji,Der Channing J.

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology,General Medicine

Link

http://www.nature.com/articles/nrd4389.pdf

Reference231 articles.

1. Cox, A. D. & Der, C. J. RAS history: The saga continues. Small GTPases 1, 2–27 (2010).

2. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).

3. Thompson, H. US National Cancer Institute's new RAS project targets an old foe. Nature Med. 19, 949–950 (2013).

4. Berndt, N., Hamilton, A. D. & Sebti, S. M. Targeting protein prenylation for cancer therapy. Nature Rev. Cancer 11, 775–791 (2011).

5. Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469–483 (2005).

Cited by 1559 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in the design of small molecular drugs with acrylamides covalent warheads;Bioorganic & Medicinal Chemistry;2024-10

2. Development of a Practical Telescoped Process to Prepare (P)-7-(2-Amino-6-fluorophenyl)-4-hydroxy-6-(trifluoromethyl)pyrido[3,4-d]pyrimidin-8(7H)-one: a Key Intermediate of KRAS^G12C Inhibitor GH35;Organic Process Research & Development;2024-09-13

3. Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer;International Journal of Molecular Sciences;2024-09-12

4. Relative Bioavailability of Sotorasib Following Administration as a Water Dispersion to Healthy Subjects and Compatibility With Enteral Administration;Clinical Pharmacology in Drug Development;2024-09-04

5. Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions;Current Oncology;2024-09-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3